A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

This study is testing a combination of three cancer treatments — ivonescimab (a dual immunotherapy drug), albumin-paclitaxel (chemotherapy), and cisplatin (chemotherapy) — given before surgery to patients with esophageal squamous cell carcinoma (a cancer of the food pipe). The goal is to shrink the tumor before surgery to improve outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with resectable (operable) esophageal squamous cell carcinoma confirmed by biopsy - Your cancer is locally advanced but has not spread to distant organs - You have good overall health (ECOG score 0–1) with adequate organ function - You are expected to survive at least 3 months and be able to undergo surgery **You may NOT be eligible if...** - You have received any prior cancer treatment - Your cancer has spread to the neck lymph nodes outside the upper chest area, or to distant organs - You have abnormal thyroid function (with certain exceptions) - You do not meet the blood count, liver, or kidney function requirements Talk to your doctor to see if this trial is right for you.